Warrant Programme - Registration of capital increase and new Articles of Association following warrant exercise

Company Announcement no. 21/2014     To: NASDAQ OMX Copenhagen A/S                                 Hørsholm, Denmark, 1 september 2014      Warrant Programme - Registration of capital increase and new Articles of Association following warrant exercise   With reference to Company Announcement no. 20/2014 of 28 august 2014, Veloxis Pharmaceuticals A/S announces that as a consequence of warrant exercise a capital increase of nominal 47,003.10 new shares with a nominal value of DKK 0.10 each has been registered with the Danish Business Authority today.   Following registration of the new shares, the share capital of Veloxis Pharmaceuticals A/S is nominal DKK 166,299,731.40 divided into shares of DKK 0.10 each.   Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S.   The new shares are expected to be admitted to trading and official listing on NASDAQ OMX Copenhagen on 3 September 2014 under the same identification code as the company's existing shares (ISIN: DK0060048148).   The amendment of the Articles of Association entailed by the capital increase has today also been registered with the Danish Business Authority. The new Articles of Association for Veloxis Pharmaceuticals A/S are attached to this announcement and are also available on the company’s website: www.veloxis.com.   For more information, please contact:   Veloxis Pharmaceuticals A/S   Bill Polvino                                          Johnny Stilou President & CEO                                   EVP, Chief Financial Officer Mobile: +1 917 647 9107                      Mobile: +45 21 227 227 Email: wjp@veloxis.com                       Email: jst@veloxis.com     About Veloxis Pharmaceuticals Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company’s lead product candidate is Envarsus® XR for immunosuppression, specifically organ transplantation. Veloxis’ unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs.  Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Salix, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.   For further information, please visit www.veloxis.com.  Vedhæftede filer:010914 Veloxis Articles of Association.pdf010914 Veloxis Announces Articles of Association.pdf